Clinical trials: Vaccine Response
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Respiratory Syncytial Virus Infections
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
The purpose of this study is to assess the safety, reactogenicity and immune responses of two doses of the investigational RSV vaccines (with different formulations), when administered intramuscularly (IM) according to a 0, 2…
- Trial name
- NCT03814590
- Testing
- RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
- Where
- 21 sites in United States, Belgium
- Volunteers
- 1,053 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Smallpox
MVA Post-Event: Administration Timing and Boost Study
The purpose of this study is to evaluate an investigational smallpox vaccine, called IMVAMUNE®, with respect to safety and immune (body's defense system) response.
- Trial name
- NCT00437021
- Testing
- Live vaccinia virus vaccine, MVA Smallpox Vaccine
- Where
- 7 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gonorrhoea
Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination
This is a Phase 2 mechanistic clinical trial to assess the systemic and mucosal immunogenicity of the multicomponent meningococcal serogroup B vaccine (4CMenB or Bexsero (R)) (group 1, 40 subjects) against Neisseria gonorrhoeae…
- Trial name
- NCT04722003
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India
The purpose of this study was to evaluate the humoral immunogenicity and safety of 2 doses of GSK Biologicals' Herpes Zoster subunit vaccine (HZ/su) administered for the prevention of Herpes Zoster (HZ) in adults aged 50 years of…
- Trial name
- NCT05219253
- Testing
- HZ/su
- Where
- 9 sites in India
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases, COVID-19
COVID-19 Vaccine Boosters in Patients With CKD
This study is a 12-month, four-arm parallel-group randomized control trial of Pfizer-BioNTech versus MODERNA COVID-19 (Corona Virus disease 2019)vaccine boosters in chronic kidney disease and dialysis patients with poor humoral…
- Trial name
- BOOST KIDNEY (NCT05022329)
- Testing
- Pfizer-BioNTech COVID-19 Vaccine, MODERNA SARS-CoV-2 Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 273 people
- Sponsor
- Sunnybrook Health Sciences Centre
Multiple Myeloma, AL Amyloidosis
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with…
- Conditions
- Multiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
- Trial name
- NCT05028374
- Testing
- A single "booster" dose of the Moderna mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Tetanus, Acellular Pertussis
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines
The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate the non-inferiority of GSK Biologicals' DTaP-IPV…
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria
- Trial name
- NCT00148941
- Testing
- SB213503 lot 1, SB213503 lot 2, SB213503 lot 3
- Where
- 24 sites in United States
- Volunteers
- 4,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccine Virus Shedding
Nasal and Systemic Immune Responses to Nasal Influenza Vaccine
Intranasal live attenuated influenza vaccine (LAIV; trade name FluMist/Fluenz-Tetra, manufactured by AstraZeneca/Medimmune) is the standard influenza vaccine given to children aged 2-17 years of age in the UK.
- Trial name
- Flu-M3 (NCT04110366)
- Testing
- Live attenuated influenza vaccine, Vehicle control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Imperial College Healthcare NHS Trust
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Influenza
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
- Trial name
- NCT01827462
- Testing
- Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Stanford University
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between the ages of 7 and 12 years.
- Trial name
- NCT00339040
- Testing
- Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic, Liver Diseases
Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection
Clearance of HCV infection requires early and multi-specific HLA class I restricted CD8+ T cell and class II restricted CD4+ T cell responses to both structural (Core) and non-structural HCV proteins (NS3, NS4A, NS5A, NS5B).
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Hepatitis, Virus Diseases
- Trial name
- NCT03119025
- Testing
- Autologous DC-vaccines
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Russian Academy of Medical Sciences
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy
This study is designed to provide data on the immune response and safety of administering vaccines to relapsing multiple sclerosis (RMS) participants taking ozanimod compared to controls taking interferon-beta's or receiving no…
- Trial name
- NCT05028634
- Testing
- Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
- Where
- 33 sites in United States, Germany
- Volunteers
- 63 people
- Sponsor
- Celgene
Rotavirus
A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)
This is a Phase I clinical trial including 2 parts to evaluate the safety and immune response to RotaTeq™ /placebo in subjects of 65 to 80 years of age.
- Trial name
- NCT00836498
- Testing
- Comparator: RotaTeq
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Neisseria Gonorrhoeae Infection
Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine
The purpose of this study is to test whether the group B meningitis vaccine (brand name Bexsero™) induces immune responses against the bacteria that causes gonorrhea.
- Trial name
- 4CMenB (NCT04094883)
- Testing
- Meningococcal Group B Vaccine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Malaria,Falciparum
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
Malaria remains one of the leading causes of morbidity and mortality worldwide. Plasmodium falciparum is a complex pathogen with numerous immune evasion mechanisms which has added layers of complexity to the development of safe…
- Trial name
- R21/Matrix-M (NCT05252845)
- Testing
- R21/Matrix-M vaccination, DHA-PIP, PQ
- Where
- Thailand
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Herpes Zoster
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
The aim of this study was to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent…
- Trial name
- NCT05047770
- Testing
- HZ/su, Flu D-QIV, mRNA-1273
- Where
- 46 sites in United States
- Volunteers
- 2,013 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults…
- Trial name
- NCT05972993
- Testing
- mRNA-CR-04 vaccine 10μg, mRNA-CR-04 vaccine 30μg, mRNA-CR-04 vaccine 100μg
- Where
- 4 sites in United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline